Pfizer, Haleon
Pfizer Intends to Sell Around 540 Million Ordinary Shares in Haleon -- Update
Pfizer said it intends to sell around 540 million ordinary shares in British consumer-healthcare business Haleon, or about 5.9% of the company's issued share capital. The pharmaceutical giant said Monday that the price per share will be determined by way of an accelerated bookbuilding process to institutional investors.
Pfizer Inc. (NYSE:PFE) is set to raise approximately £2.7 billion ($3.6 billion) through the sale of shares in Haleon Plc, as ...
Pfizer intends to sell about 540 million shares in British consumer healthcare company Haleon, a bookrunner said on Monday, ...
Pfizer Inc. plans to sell 540 million worth of shares in Haleon Plc, as it pares back its holding in the UK consumer health ...
Goldman Sachs, JP Morgan, Morgan Stanley and UBS are global coordinators on the trade, with Barclays, Bank of America, BNP ...
From US drugmaker Pfizer's stake sale in Sensodyne maker Haleon to Beijing joining the list of Chinese cities easing ...
Dr Reddy's Laboratories on Monday said its Switzerland-based subsidiary has completed the acquisition of Haleon plc's global ...
Pfizer Inc. announced a further reduction of its stake in Haleon Plc, offering to sell about a 5.9% stake in the UK consumer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback